Walmsley has ordered a greater concentration of R&D spending on fewer, higher priority drugs. To this end, GSK says it has now cut 30 pre-clinical and clinical programmes.

Speculation is mounting GlaxoSmithKline's CEO Emma Walmsley may pay the price for the company’s lacklustre performance, after the dreaded activist investor Elliott Management built a stake in ...

A man who pretended he had won £8.4million on the National Lottery was jailed for three years yesterday for a string of deceptions involving thousands of pounds worth of dud cheques ...